ProMIS NeurosciencesPMN -5.00%32 3-Year ROIIC % is -28,943.10 as of Dec. 2025. GuruFocus rates PMN with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,321 Biotechnology companies, ProMIS Neurosciences ranks worse than 99.85% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ProMIS Neurosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -28,943.10%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ProMIS Neurosciences's 3-Year ROIIC % or its related term are showing as below:
PMN's 3-Year ROIIC % is ranked worse than 99.85% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs PMN: -28943.10
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ProMIS Neurosciences 3-Year ROIIC % Related Terms
ProMIS Neurosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMN vs BMEA, ANIX, ATRA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, ProMIS Neurosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's 3-Year ROIIC % falls into.
ProMIS Neurosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -40.167 (Dec. 2025) - -23.38 (Dec. 2022) )
/
( 0.08 (Dec. 2025) - 0.022 (Dec. 2022) )
=
-16.787
/
0.058
=
-28,943.10%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ProMIS Neurosciences (PMN) has a 3-Year ROIIC % of -28,943.10 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #1319 out of 1321 companies in the Biotechnology industry, placing it in the top 99.8%.
Is ProMIS Neurosciences' 3-Year ROIIC % too high?
ProMIS Neurosciences' current 3-Year ROIIC % is -28,943.10. Based on the distribution chart, ProMIS Neurosciences ranks #1319 out of 1321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' 3-Year ROIIC % compare to BMEA and ANIX?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #1319 out of 1321 companies for 3-Year ROIIC %. This places ProMIS Neurosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current 3-Year ROIIC % is -28,943.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current 3-Year ROIIC % of -28,943.10. The current 3-Year ROIIC % is -28,943.10. ProMIS Neurosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current 3-Year ROIIC % is -28,943.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
32GF Score
Get the complete analysis for PMN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
